Evaluation of a novel biphasic calcium phosphate in standardized bone defects: a histologic and histomorphometric study in the mandibles of minipigs.
OBJECTIVE
A novel biphasic calcium phosphate (CaP) granulate consisting of hydroxyapatite (HA) and beta-tricalciumphosphate (TCP) was compared with pure HA and pure TCP and with autograft as positive control.


METHODS
Four standardized bone defects were prepared in both mandibular angles of 16 minipigs and grafted with autogenous bone chips, HA, HA/TCP (60% : 40%), or TCP. Histologic and histomorphometric analysis of bone formation and graft degradation followed healing periods of 2, 4, 8, and 24 weeks.


RESULTS
2 weeks: more bone formation in defects filled with autograft than with the three CaP materials (P<0.05). 4 weeks: bone formation differed significantly (P<0.05) between all four materials (autograft>TCP>HA/TCP>HA). 8 weeks: more bone formation in defects with autograft and TCP than with HA/TCP (P<0.05), and HA/TCP had more bone formation than HA (P<0.05). 24 weeks: no difference in bone formation between the groups. Autograft and TCP resorbed quickly and almost completely over 8 weeks, whereas HA/TCP and HA showed limited degradation over 24 weeks.


CONCLUSIONS
All defects healed with mature lamellar bone and intimate contact between bone and the remaining graft material. The rate of bone formation corresponded to the content of TCP in the CaP materials.
Jensen
Simon Storgård
SS
Department of Oral Surgery and Stomatology, School of Dental Medicine, University of Berne, Berne, Switzerland. simon.storgaard@jensen.mail.dk
Yeo
Alvin
A
Dard
Michel
M
Hunziker
Ernst
E
Schenk
Robert
R
Buser
Daniel
D
D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D018786:Bone Substitutes / Q000008:administration & dosage / Q000627:therapeutic use*; D016025:Bone Transplantation / Q000379:methods*; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D004338:Drug Combinations; D017886:Durapatite / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D005500:Follow-Up Studies; D008334:Mandible / Q000187:drug effects / Q000601:surgery*; D016348:Osseointegration / Q000187:drug effects; D010012:Osteogenesis / Q000187:drug effects; D013552:Swine; D013556:Swine, Miniature
D001672:Biocompatible Materials; D018786:Bone Substitutes; D002130:Calcium Phosphates; D004338:Drug Combinations; C485817:beta-tricalcium phosphate; D017886:Durapatite